-
-
-
-
-
-
-
Medicus Pharma Reports Full-Year 2025 Financial Results and Provides Corporate Update
-
-
-
-
-
-
-
Medicus Pharma on Bloomberg World
-
-
-
-
-
-
-
Medicus Pharma study shows stable bone turnover with hormone suppression
-
-
-
-
-
-
-
Medicus Pharma Ltd. Completes Enrolment of Ninety (90) Patients for Phase 2 Clinical Study (SKNJCT-003) to Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin
-
-
-
-
-
-
-
Medicus Pharma Ltd. Appoints Carolyn Bonner as Chief Financial Officer in Addition to Her Role as President
-
-
-
-
-
-
-
Medicus Pharma receives UK approvals to expand BCC skin cancer trial
-
-
-
-
-
-
-
Medicus Pharma Ltd. Announces First Patient Treated in United Arab Emirates (UAE) Sknjct-004 Phase 2 Clinical Study to Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin
-
1,185,382 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

